<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA approval on FinanClub</title>
    <link>https://finan.club/tags/fda-approval/</link>
    <description>Recent content in FDA approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 22 Jan 2024 09:05:50 +0000</lastBuildDate><atom:link href="https://finan.club/tags/fda-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Mon, 22 Jan 2024 09:05:50 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:153
Chances: Merck &amp;amp; Co., Inc. has a strong portfolio of pharmaceutical, vaccine, and animal health products, positioning it well for future growth and profitability. The recent FDA approval for expanded use of Keytruda in combination with chemoradiotherapy for advanced cervical cancer is a significant positive development for the company.</description>
    </item>
    
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Thu, 28 Dec 2023 09:05:11 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:64
Chances: ImmunityBio, Inc. is participating in the 35th Annual Piper Sandler Healthcare Conference, which is a positive sign for potential collaborations and investor interest. The new data showing the potential benefits of Memory Cytokine-Enriched Natural Killer cells (M-ceNK) for patients with small cell lung cancer and other types of neuroendocrine tumors indicates promising developments in the companyâ€™s immunotherapy platform.</description>
    </item>
    
  </channel>
</rss>
